When was BillionToOne founded?

BillionToOne was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is BillionToOne located?

BillionToOne is headquartered in San Francisco, United States. It is registered at Menlo Park, California.

Who is the current CEO of BillionToOne?

Oguzhan Atay of BillionToOne. They have also founded 2 companies.

How many employees does BillionToOne have?

As of Apr 30, 2026, the latest employee count at BillionToOne is 767.

Is BillionToOne a funded company?

BillionToOne is a funded company, having raised a total of $389M across 10 funding rounds to date. The company's 1st funding round was a $120K Seed round, raised on 2017.

When was the latest funding round of BillionToOne?

BillionToOne's latest funding was a $130M Series D round on Jun 21, 2024, with participation from 8 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $424M in funding in 2026 to date.

Is BillionToOne a Genomics company?

The primary sectors of BillionToOne are Genomics, Women Health and Oncology.

Where does BillionToOne rank among its competitors?

BillionToOne ranks 8th amongst 532 active competitors, of which 154 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Delfi Diagnostics, which secured $34.3M in Dec, 2025.

Who are the top competitors of BillionToOne?

BillionToOne's top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Delfi Diagnostics secured the most recent funding round in December, 2025.

BillionToOne - 2026 Company Profile, Team, Funding & Competitors

Sectors and market segments that BillionToOne operate in

BillionToOne serves in the Life Sciences, Sustainability Tech market segments.The primary business model of BillionToOne are:

Company Details

Provider of cell-free cancer liquid biopsy test. The company provides a molecular counter platform to count the DNA molecules from blood samples. It provides genetic tests for cystic fibrosis, spinal muscular atrophy, sickle cell disease, etc.

Website: www.billiontoone.com/
Social
Registered Address: Menlo Park, California

Key Metrics

Founded Year

2015

Location

San Francisco, United States

Stage

Public

Total Funding

$389M in 10 rounds

Latest Funding Round

Series D, Jun 21, 2024, $130M

Investors

Hummingbird Ventures & 30 more

Ranked

8^th among 532 active competitors

Employee Count

767 as on Apr 30, 2026

Similar Companies

Guardant Health & 664 more

Exit Details

Public

View BillionToOne's full profile

BillionToOne is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Billiontoone, Inc. CIN: 811082020 , United States, Active	Dec 31, 1999	-	468 (As on Dec 31, 2024)	-
Billiontoone, Inc. CIN: 0018y00000BhtwJAAR , United States, Active	Apr 16, 2024	-	-	-
BillionToOne Inc CIN: 81-1082020 , United States, Active	Dec 31, 2014	-	47 (As on Dec 31, 2020)	-

BillionToOne got listed on Nov 06, 2025.

Click here to take a look at BillionToOne's IPO in detail

BillionToOne has raised a total funding of $389M over 10 rounds. Its first funding round was on 2017. Its latest funding round was a Series D round on Jun 21, 2024 for $130M. 8 investors participated in its latest round. BillionToOne has 31 institutional investors.

Here is the list of recent funding rounds of BillionToOne:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 21, 2024	$130M	Series D	-	-	Premji Invest	Neuberger Berman, Adams Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, Fifty Years
Dec 15, 2022	$48.5M	Series C	-	-	Baillie Gifford, Adams Street Partners, Time BioVentures	Libertus Capital, Hummingbird Ventures, Neotribe, Fifty Years, Norwest
Dec 15, 2022	Undisclosed	Conventional Debt	-	-	-	Bridge Community Bank

Access funding benchmarks and valuations. Sign up today!

View details of BillionToOne's funding rounds and investors

The founders of BillionToOne are Oguzhan Atay and Sukrit Silas. Oguzhan Atay is the CEO of BillionToOne.

Here are the details of BillionToOne's key team members:

Oguzhan Atay: Co-Founder & CEO of BillionToOne and founder of 1 other company.
Contact Info: 2 email addresses
Sukrit Silas: Former Co-Founder of BillionToOne.

View details of BillionToOne's Founder profiles and Board Members

BillionToOne's employee count trend

BillionToOne has 767 employees as of Apr 26. Here is BillionToOne's employee count trend over the years:

Uncover BillionToOne's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BillionToOne include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of BillionToOne, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Orbimed, Sequoia Capital & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Harmony Venture Partners ... & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Casdin Capital & 11 others	71/100
5th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
6th	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
7th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Beyond Ventures, Ping An Ventures & 21 others	70/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Adams Street Partners, Baillie Gifford & 29 others	69/100
9th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	Orbimed, Merck Global Health Innovation Fund ... & 19 others	68/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Civilization Ventures & 6 others	66/100